Literature DB >> 26260383

Commonality of rituximab pharmacokinetic disposition in nephrotic syndrome and autoimmune cytopenias in chronic lymphocytic leukemia patients.

Nuggehally R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26260383     DOI： 10.1007/s00467-015-3187-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.

Authors:  Clifton C Mo; Ndegwa Njuguna; Paul V Beum; Margaret A Lindorfer; Berengere Vire; Elinor Lee; Gerald Marti; Wyndham H Wilson; Ronald P Taylor; Adrian Wiestner
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

2.  Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome.

Authors:  Clare E Counsilman; Cornelia M Jol-van der Zijde; Jasper Stevens; Karlien Cransberg; Robbert G M Bredius; Ram N Sukhai
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

3.  An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Authors:  Mona Darwish; John M Burke; Edward Hellriegel; Philmore Robertson; Luann Phillips; Elizabeth Ludwig; Mihaela C Munteanu; Mary Bond
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-28       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.